🇺🇸 FDA
Pipeline program

VAY736, TENOFOVIR ALAFENAMIDE, ENTECAVIR , -, VAY736, VAY736, TENOFOVIR DISOPROXIL

CVAY736A2202

Phase 2 small_molecule active

Quick answer

VAY736, TENOFOVIR ALAFENAMIDE, ENTECAVIR , -, VAY736, VAY736, TENOFOVIR DISOPROXIL for Rheumatoid Arthritis, Sjögren’s Disease, Systemic Lupus erythematosus is a Phase 2 program (small_molecule) at Novartis Ophthalmics Europe with 1 ClinicalTrials.gov record(s).

Program details

Company
Novartis Ophthalmics Europe
Indication
Rheumatoid Arthritis, Sjögren’s Disease, Systemic Lupus erythematosus
Phase
Phase 2
Modality
small_molecule
Status
active

Clinical trials